Details of the Drug
General Information of Drug (ID: DMHXTNW)
Drug Name |
LY-2228820
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Ralimetinib; 862505-00-8; LY-2228820 free base; UNII-73I34XW4HD; 73I34XW4HD; 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-3H-Imidazo[4,5-b]pyridin-2-amine; C24H29FN6; Ralimetinib [USAN:INN]; LY2228820 free base; Ralimetinib (USAN/INN); GTPL7959; SCHEMBL3989306; SCHEMBL13826263; CHEMBL2364626; DTXSID00235456; MolPort-009-679-493; XPPBBJCBDOEXDN-UHFFFAOYSA-N; BCPP000180; BCP02033; ZINC34630490; ABP000309; 2526AH; ABP000548; AKOS027282678; SB16635; BCP9000871; DB11787; NCGC00346537-05; LY-2180895; LY-2211877; LY-2228820 mesylate; LY-2231377; LY-2322600; LY-479754; LY-22288202MsOH; P38 MAP kinase inhibitors (inflammation, cancer), Lilly
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure |
![]() |
|||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 420.5 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 5.3 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 5 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
References